Boston Scientific (BSX) reported Q2 adjusted earnings Wednesday of $0.75 per diluted share, up from $0.62 a year earlier.

Analysts polled by FactSet expected $0.73.

Net sales for the quarter ended June 30 were $5.06 billion compared with $4.12 billion a year earlier.

Analysts surveyed by FactSet expected $4.89 billion.

For Q3, the company expects adjusted EPS of $0.70 to $0.72. Analysts are looking for $0.70.

Net sales for the quarter are projected to rise 17% to 19%, according to the company.

For 2025, Boston Scientific said it now expects adjusted EPS of $2.95 to $2.99 versus its prior outlook range of $2.87 to $2.94. Analysts are looking for $2.92.

The company now projects full-year net sales growth at 18% to 19% versus its previous guidance range of 15% to 17%.

Boston Scientific shares were up 1% in recent premarket activity.